Skip to Main Content

Paper Details

Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood.
J Pathol
3
2021
AKT, Cancer, Children, MYOD1, MYOD1 and PIK3CA mutations, MYOD1 hotspot, MYOD1 hotspot mutation, MYOD1 p.L122R mutation, MYOD1-mutant sarcomas, PI3K, PIK3CA, PIK3CA mutations, PTEN, TSC2, Tumor, Tumor DNA, children, embryonal rhabdomyosarcomas, mTOR, myogenic differentiation 1 gene, p.L122R, patient, patient-derived xenograft models, patients, sclerosing rhabdomyosarcoma, soft-tissue sarcoma, soft-tissue sarcomas, spindle, spindle and/or round cells, spindle cell/sclerosing rhabdomyosarcomas, tumor, tumors, variant
Author NameAffiliation
Sarah ScollonBaylor College of Medicine
Sharon E PlonBaylor College of Medicine
Sharon E PlonBaylor College of Medicine
Sharon E PlonBaylor College of Medicine
Sharon E PlonThe Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Murali ChintagumpalaBaylor College of Medicine
Murali ChintagumpalaThe Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Angshumoy RoyBaylor College of Medicine
Angshumoy RoyBaylor College of Medicine
Angshumoy RoyTexas Children's Hospital
Angshumoy RoyThe Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Donald W ParsonsBaylor College of Medicine
Donald W ParsonsBaylor College of Medicine
Donald W ParsonsBaylor College of Medicine
Donald W ParsonsBaylor College of Medicine
Donald W ParsonsThe Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Donald W ParsonsBaylor College of Medicine
Donald W ParsonsBaylor College of Medicine
Donald W ParsonsBaylor College of Medicine
Donald W ParsonsBaylor College of Medicine
Donald W ParsonsThe Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
  • 1 - 21

Datasets

Release 1.2